Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset

Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset

Introduction: Significant improvement in progression-free survival (PFS; primary end point) was reported in the phase 3 RELAY study with ramucirumab (RAM) plus erlotinib (ERL) versus placebo (PL) in untreated EGFR-mutated NSCLC (hazard ratio [HR] = 0.59, 95% confidence interval [CI]: 0.46–0.76, p &l...

Full description

Saved in:
Bibliographic Details
Main Authors: Makoto Nishio, MD, PhD, Takashi Seto, MD, PhD, Martin Reck, PhD, Edward B. Garon, MD, Kazuto Nishio, MD, PhD, Kazuo Kasahara, MD, PhD, Kazumi Nishino, MD, PhD, Miyako Satouchi, MD, PhD, Kiyotaka Yoh, MD, Hidetoshi Hayashi, MD, PhD, Kazuko Sakai, PhD, Sotaro Enatsu, MD, PhD, Bente Frimodt-Møller, MSc, Tomoko Matsui, Sunoj Chacko Varughese, MSc, Michelle Carlsen, MS, Carla Visseren-Grul, MD, Kazuhiko Nakagawa, MD, PhD
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:JTO Clinical and Research Reports
Subjects:
Non-small-cell lung carcinoma
Japan
Ramucirumab
EGFR
Overall survival
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364325000359
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items